Henry Schein (HSIC) was Initiated by Deutsche Bank to “Hold” and the brokerage firm has set the Price Target at $174. Deutsche Bank advised their Clients and Investors in a research report released on Mar 15, 2017.
Based on several research reports , Deutsche Bank Initiated Henry Schein on Mar 15, 2017 to “Hold”, Price Target of the shares are set at $174.Company shares were Reiterated by Barrington Research on Feb 22, 2017 to “Outperform”, Firm has raised the Price Target to $ 196 from a previous price target of $185 .Gabelli & Co Upgraded Henry Schein on Jan 10, 2017 to ” Buy”, Price Target of the shares are set at $208.Company shares were Upgraded by Robert W. Baird on Jan 3, 2017 to ” Outperform”, Firm has raised the Price Target to $ 170 from a previous price target of $164 .
Several company insiders have filed Insider transactions , on Mar 9, 2017, Philip A Laskawy (director) sold 1,103 shares at $171.51 per share price. According to the SEC, on Mar 9, 2017, James A. Harding (SVP, Chief Technology Officer) sold 10,552 shares at $171.60 per share price. On Mar 8, 2017, James P Breslawski (Pres., HSI & CEO Global Dental) sold 8,486 shares at $170.35 per share price, according to the Form-4 filing with the securities and exchange commission.
On the company’s financial health, Henry Schein reported $1.88 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Feb 21, 2017. Analyst had a consensus of $1.84. The company had revenue of $3120.93 million for the quarter, compared to analysts expectations of $3071.49 million. The company’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.67 EPS.
Henry Schein opened for trading at $171.51 and hit $173.13 on the upside on Wednesday, eventually ending the session at $172.72, with a gain of 0.86% or 1.47 points. The heightened volatility saw the trading volume jump to 3,39,618 shares. Company has a market cap of $13,679 M.
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.